🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    Verona Pharma Ireland Limited

    Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy

    phase 2 small molecule active

    1 trial

  2. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets, ART6043, ART6043, ART6043, ART6043, ART6043

    Lacuna Pharma Pty Ltd

    Metastatic solid tumors, Advanced solid tumors

    phase 2 small molecule active

    1 trial

  3. MAS825, -

    Novartis Pharmaceuticals

    Still’s disease

    phase 2 small molecule active

    1 trial

  4. MB07133 300mg/m2/day

    LIGAND PHARMACEUTICALS INC

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  5. MB07803

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  6. MB07811

    LIGAND PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule terminated

    1 trial

  7. MBG453, VENETOCLAX, VENETOCLAX, AZACITIDINE, VENETOCLAX

    Novartis Pharmaceuticals

    intermediate, high or very high risk MDS in adult patients chronic Myelomonocytic Leukemia - 2 (CMML-2) Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy

    phase 2 small molecule active

    1 trial

  8. MD-0727

    IRONWOOD PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  9. MD-1100 Acetate

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome

    phase 2 small molecule completed

    1 trial

  10. MD-1100 Acetate

    IRONWOOD PHARMACEUTICALS INC

    Constipation

    phase 2 small molecule completed

    1 trial

  11. MD-7246

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Diarrhea (IBS-D)

    phase 2 small molecule completed

    1 trial

  12. METFORMIN , Placebo 515

    Pari Pharma GmbH

    Portal hypertension (PHT) and consequences in complications of cirrhosis

    phase 2 small molecule active

    1 trial

  13. METHYLPREDNISOLONE, METHYLPREDNISOLONE, IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., GLUCOSE 5 % B.BRAUN, solution pour perfusion

    Pari Pharma GmbH

    Fulminant myocarditis

    phase 2 small molecule active

    1 trial

  14. METHYLPREDNISOLONE, METHYLPREDNISOLONE, METHYLPREDNISOLONE HYDROGEN SUCCINATE, METHYLPREDNISOLONE , METHYLPREDNISOLONE, METHYLPREDNISOLONE, METHYLPREDNISOLONE

    Pari Pharma GmbH

    NEUROENDOCRINE CELLS HYPERPLASIA OF INFANCY

    phase 2 small molecule active

    1 trial

  15. METRONIDAZOLE, FOSFOMYCIN, MOLGRAMOSTIM

    Lacuna Pharma Pty Ltd

    Pouchitis

    phase 2 small molecule active

    1 trial

  16. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  17. MGL-3196 (resmetirom)

    Madrigal Pharmaceuticals EU Limited

    Heterozygous Familial Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  18. MHS-1031

    CATALYST PHARMACEUTICALS, INC.

    Gastroesophageal Reflux

    phase 2 small molecule active

    1 trial

  19. MITAPIVAT

    Lacuna Pharma Pty Ltd

    Sickle Cell Disease (SCD) and Nephropathy

    phase 2 small molecule active

    1 trial

  20. MKC-1

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  21. MKC-1

    CASI Pharmaceuticals

    Advanced Cancer

    phase 2 small molecule completed

    2 trials

  22. MKC-1

    CASI Pharmaceuticals

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  23. MKC-1

    CASI Pharmaceuticals

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  24. MMV390048 40mg

    CNS Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources